Gland Pharma: The selling by Morgan Stanley was seen amid a two-day selloff in shares of Gland Pharma where the scrip has lost one-third of its market value following a disappointing quarterly results. The buyer could not be ascertained.
The drugmaker reported a 72 per cent YoY drop in net profit to Rs 79 crore in Q4FY23 due to a production shutdown at one of its facilities in Telangana and soft demand.